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Abstract
Background: Hepatocellular carcinoma has a dismal prognosis due to recurrence rates of up to 70% after curative
resection. Early recurrence is driven by synchronous microscopic intrahepatic metastases. The predictive value of
histological parameters is discussed controversially and adjuvant therapy is not established. The aim of this study
was to identify patients at high risk for early intrahepatic recurrence by expression profiling of selected micro RNAs.
Methods: In 52 patients undergoing HCC resection between 2011 and 2014, liver and tumor tissue was collected
during surgery. Twelve patients with incomplete data regarding HCC recurrence, secondary liver transplantation, or
perioperative death were excluded, leaving 40 patients with early recurrence <12 months (R+) or without
recurrence for >24 months (R-) to compare grading, T, L, V, and R status. If tissue quality permitted, micro RNAs
were measured in HCC and liver tissue.
Results: Ten women and 30 men (64.0 ± 10.2 years) were analyzed. R+ occurred in 29 patients 6.2 ± 4.5 months
after resection. Surveillance of R- was 26.2 ± 5.2 months. High intratumoral expression of miR-135a was associated
with high risk of recurrence (HR = 4.2, p = 0.024, time to recurrence 8.8 ± 2.0 vs. 24.8 ± 4.4 months in patients with
low miR-135a expression). As expected, T3 status was correlated with early recurrence, while other histological
parameters and expression of miR-21, miR-122, and miR-125a did not.
Conclusions: We show a significant association between high expression of miR-135a and early HCC recurrence.
Therefore, high intratumoral miR-135a expression might serve as a novel biomarker to identify patients urgently
requiring adjuvant therapy post resection.
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Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon neoplasm in men and the third most frequent
cause of cancer death worldwide [1]. HCC is staged ac-
cording to the Barcelona Clinic Liver Cancer (BCLC)
classification system. Very early and early stage HCC
(BCLC 0 and A) are treated with liver resection (LR), ab-
lation, or transplantation [1]. Despite these potentially
curative treatment options, 50–70% of patients suffer
from intrahepatic recurrence of HCC after LR or abla-
tion, thus resulting in an overall dismal prognosis [2].
Two patterns of intrahepatic recurrence have been
established, dividing the group into early (up to 2 years
after LR) and late recurrence (more than 2 years after
LR). In the majority of cases, early recurrence is caused
by microscopic metastatic spread before LR, while late
recurrence is driven by the oncogenic environment of
the underlying chronic liver disease and most likely in-
stigated by de novo transformation. Along this line,
vascular invasion (macroscopic invasion by imaging or
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microscopic invasion in histopathology) and/or non-
anatomical resection on the one hand, and multiplicity
of tumor nodules and/or poor degree of differentiation
on the other hand, are controversially debated as risk
factors for early and late recurrence of HCC. Recently,
new markers, including specific gene signatures, have
been explored to stratify the risk of recurrence and to
improve management of HCC, however, predictive
biomarkers are still urgently needed [3, 4].
Micro RNAs
Micro RNAs (miRNAs) are small non-coding RNAs
involved in several physiological and pathological pro-
cesses, such as cell growth and differentiation, inflamma-
tion, and carcinogenesis by regulating gene expression
on a post-transcriptional level [5, 6]. Initially, miRNAs
are transcribed as primary miRNAs, processed into pre-
cursor miRNAs, and exported to the cytoplasm to form
small miRNA duplexes. The passenger miRNA is typic-
ally degraded, while the guiding miRNA strand is incor-
porated into the RNA-induced silencing complex (RISC)
to mediate messenger RNA (mRNA) degradation or
translational inhibition depending on the base pairing
between miRNA and target mRNA [7, 8]. Regarding
tumor formation, miRNAs may function as oncogenes
or tumor suppressor genes, depending on the target
mRNA and its functional role in carcinogenesis [9]. In
chronic liver disease, numerous miRNAs have been
investigated with regard to fibrogenesis, activity of viral
hepatitis, and HCC formation [10]. Several miRNAs and
their function in HCC have recently been reviewed [8, 11].
Micro RNA 21 (miR-21) belongs to the most widely over-
expressed miRNAs in cancer and acts as an oncogene
[12]. In HCC, miR-21 upregulation is associated with
cellular proliferation and tumor growth via AKT/ERK
[13]. Also, because its expression is inversely correlated
with its target gene programmed cell death 4 (PDCD4),
miR-21 is involved in cell migration and tumor invasion
[14]. Micro RNA 122 (miR-122) is liver specific and plays
a role in hepatocyte differentiation, viral hepatitis, and
HCC development as a tumor suppressor. MiR-122 is
linked to migration, invasion, angiogenesis, and intrahepa-
tic metastasis via ADAM17, a transmembrane protease
involved in inflammation, cellular regeneration, and can-
cer development [15, 16]. Micro RNA 125b (miR-125b)
acts primarily as a tumor suppressor in HCC by target-
ing Bcl-2 and inducing cancer cell apoptosis [17]. It
also inhibits cell migration and invasion by targeting
LIN28B, and has recently been connected to epithelial-
mesenchymal transition in HCC [18, 19]. The func-
tional role of micro RNA 135a (miR-135a) in hepato-
carcinogenesis has lately been characterized in several
studies. Interestingly, Liu et al. showed that overexpres-
sion of miR-135a favours an invasive and metastatic
behaviour of HCC in vitro and is associated with malig-
nant portal vein thrombosis in vivo, most likely by directly
targeting metastasis suppressor 1 (MTSS1) [20]. Two
other studies showed that miR-135a also down-regulates
Krüppel-like factor 4, up-regulates the expression of
matrix metalloproteinase-2 and Akt, and down-regulates
forkhead box O1, resulting in higher proliferation and
invasiveness of HCC cells [21, 22].
Aim
Reliable markers to predict the risk of early intrahepatic
recurrence after complete surgical removal of HCC are
urgently needed, especially to advance the development
of adjuvant therapies, and to improve overall outcome.
Based on the current paradigm that early recurrence of
HCC is due to intrahepatic microscopic cancer dissem-
ination, the aim of this study was to evaluate selected
miRNAs potentially regulating invasion and metastatic
spread in the resected HCC tissue.
Methods
Clinical specimens
The local ethics board approved the study (PV3578). We
included 52 patients suffering from early stage HCC
who underwent partial LR at the University Medical
Center Hamburg-Eppendorf, Hamburg, Germany be-
tween May 2011 and May 2014. Prior to sample collec-
tion, we obtained informed consent. Patients with
incomplete data regarding HCC recurrence, secondary
liver transplantation, or death within 30 days after LR
were excluded. Further analysis was conducted in 40
patients. Histopathology results were obtained from the
Institute of Pathology, University Medical Center
Hamburg-Eppendorf, Hamburg, Germany. All patients
had histologically proven HCC. A flow chart of the study
design with the number of patients at each stage and
reasons for exclusion is displayed in Fig. 1.
Healthy liver controls
Liver tissue from three patients who underwent LR for
benign tumors (focal nodular hyperplasia or adenoma)
served as healthy liver controls. Liver tissue of these
patients was free from fibrosis and steatosis was <20%.
Tissue collection, total RNA isolation, reverse
transcription, and quantitative expression analysis
Following LR, HCC tissue and tissue from the surround-
ing non-cancerous liver were immediately transferred to
Allprotect tissue reagent (Qiagen, Hilden, Germany) and
stored at -80 °C until further examination. Total RNA
including miRNAs was isolated in a pairwise fashion
from HCC tissue and the surrounding non-cancerous
liver tissue using the miRNeasy Mini Kit (Qiagen). Con-
centration of total RNA was measured with NanoDrop
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technology (Thermo Fisher Scientific, Waltham, MA,
USA). Total RNA was reverse transcribed to cDNA
using the miScript II RT Kit (Qiagen). Quantitative poly-
merase chain reaction (qPCR) was performed in a 384-
well plate using the miScript SYBR Green PCR Kit, miS-
cript Universal Primer (reverse primer), and the Quanti-
Tect SYBR Green PCR Master Mix (all from Qiagen).
The reaction mix contained 2.5 ng of sample cDNA.
Primers against miR-21, miR-122, miR-125b, miR-135a
were obtained from Qiagen. Detailed sequences of tar-
geted miRNAs are displayed in Additional file 1: Table S2.
As assay control, the housekeeper miRNA RNU6-6p was
amplified. HuH7 cells, a human HCC cell line, were used
to functionally validate the primers. Three patients with
history of transarterial chemoembolization (TACE) prior
to the resection had to be excluded because of substantial
necrosis in the resected HCC.
Statistical analysis
qPCR was performed in triplicates. Data are presented
as median or mean ± standard deviation (STD). Regard-
ing miRNA analysis, healthy liver controls were utilized
as calibrator. The derived expression in each sample is
displayed as fold change compared to the calibrator.
Statistical analysis was performed with Fisher’s exact
test, Cox regression, and Kaplan-Meier curves using
IBM SPSS Statistics Version 22 (IBM, Armonk, NY,
USA) and GraphPad Prism Version 4 (GraphPad Soft-




Twelve of 52 patients were excluded from our analysis
because of incomplete data regarding HCC recurrence,
secondary liver transplantation, or death within 30 days
after operation, leaving 40 patients for further investiga-
tion. This cohort contained 10 female and 30 male (75%)
patients with a mean age of 64.6 ± 9.4 years. Fifteen
(38%) patients had liver cirrhosis, 5 patients received
TACE prior to surgical therapy, and 4 patients had pre-
vious LR. Etiologies of the underlying liver disease were
viral hepatitis (n = 11), alcohol abuse [7], non-alcoholic
steatohepatitis (NASH; 5), hemochromatosis [1], primary
biliary cholangitis with secondary autoimmune hepatitis
[1], and cryptogenic [15]. After LR, surveillance of
patients was performed by imaging studies every three
months for at least two years. Recurrence was diag-
nosed according to current imaging guidelines
(RECIST) or confirmed by biopsy if imaging was not
conclusive. Early recurrence occurred in 29 patients at
6.2 ± 4.6 months following LR. Mean surveillance of
11 patients without recurrence was 26.2 ± 5.4 months.
Demographic characteristics of each group are listed
in Table 1. Gender and age were equally distributed,
while more patients in the early recurrence group had
a history of prior treatment. The proportion of
patients with liver cirrhosis was lower in the early
recurrence group compared to patients without
recurrence (31% vs. 55%, n.s.).
Fig. 1 Study design. Displayed are the numbers of patients in each
stage of the study and reasons for exclusion
Table 1 Demographic characteristics of patients with and





Male (%) 8 (73%) 22 (76%)
Mean age at time of
resection ± STD




Liver cirrhosis (%) 6 (55%) 9 (31%)





Grade 1/2/3a 2/8/0 8/20/1
T 1/2/3a 6/4/0 9/8/11
V 0/1a 6/4 15/12
R 0/1a 10/0 25/3
Time to event Mean surveillance
26.2 ± 5.4 months
RFS 6.2 ± 4.6
months
aIn three patients complete histological analysis was not possible due to
tumor necrosis because of prior TACE. Abbreviations: RFS recurrence free
survival, TACE transarterial chemoembolization
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Correlation of histopathological results with early HCC
recurrence
We investigated, whether grading and tumor staging
parameters according to TNM classification were corre-
lated with early HCC recurrence. Due to the small sam-
ple size, the analysis was performed nonparametric. As
expected, T3 status, incorporating large tumors and
multiple tumor nodules, was significantly correlated with
early HCC recurrence compared to T1 and T2 tumors.
All 11 patients with T3 status had early recurrence,
while only 17 out of 27 patients with T1 or T2 status
experienced early recurrence (p = 0.018). In our cohort,
histological grading (G) and vascular invasion (V) were
not significantly correlated with early recurrence (Table 2).
Three patients had a positive resection margin (R1 status),
and as expected, all of them developed early recurrence;
one patient had an intrahepatic recurrence distant from
the primary tumor, the other two patients showed intra-
and extrahepatic spread at time of recurrence.
Correlation of miRNA expression with early HCC recurrence
Tissue quality permitted miRNA expression analysis in 26
patients (n = 8 without recurrence, n = 18 with early recur-
rence). Figure 2 shows box-and-whisker-plots of the
derived expression levels for miR-21, miR-122, miR-125b,
and miR-135a in HCC tissue and the surrounding non-
cancerous liver tissue on a log scale as fold expression
compared to the calibrator (healthy liver controls). Mean
expression of miR-21 and miR-135a are significantly
elevated in HCC tissue vs. the surrounding non-cancerous
liver tissue (6.85 ± 5.86 vs. 2.58 ± 1.22, p = 0.003; and
20.37 ± 34.81 vs. 3.57 ± 4.13, p = 0.04). The mean expres-
sion of miR-122 and miR-125b are decreased in HCC
tissue without reaching statistical significance in this small
cohort of patients (1.11 ± 0.81 vs. 3.28 ± 5.41, p = 0.05; and
1.99 ± 4.13 vs. 3.84 ± 7.64, p = 0.3).
The mean expression of each miRNA in the surround-
ing non-cancerous liver tissue was used as a threshold to
divide patients into high and low expressors to allow a
dichotomous and nonparametric analysis. Cox regres-
sion analysis revealed an increased hazard ratio (HR) of
4.2 with a 95% confidence interval (CI) from 1.2 to 14.8
for high expressors of miR-135a and a significance level
of p = 0.024 (see Table 3). Figure 3a shows the corre-
sponding Kaplan-Meier curve with a significantly lower
recurrence free survival (RFS) in high expressors of miR-
135a. Mean time to recurrence was 8.8 ± 2.0 months in
high expressors compared to 24.8 ± 4.4 months in low
miR-135a expressors. In total, 14 out of 16 patients with
high expression of miR-135a had an early recurrence,
resulting in a specificity of 88%. The analysis of miR-21
expression showed a similar trend with lower RFS in
high expressors of miR-21, but did not reach the defined
level of significance (p = 0.203, see Fig. 3b).
Analysis of potential confounders and miR-135a
expression
Three patients, all within the early recurrence group,
were not completely resected (R1-status, see Table 2).
Also, the existence of liver cirrhosis was not distributed
equally between both groups (see Table 1). To investi-
gate the influence of these potential confounders a
covariate Cox regression analysis with miR-135a expres-
sion and these variables was performed showing no in-
fluence of resection status or existence of liver cirrhosis
on the correlation between high miR-135a expression
and early recurrence (see Table 3). As mentioned above,
the widely accepted correlation of T3 status and early
recurrence was also significant in our cohort. T3-status
was significantly associated with high expression of miR-
135a. All 10 patients with T3 showed high expression of
miR-135a (p = 0.002) and all of these patients experi-
enced early recurrence (100%). Within the group of
patients with T1- or T2-status (n = 16), 5 out of 7
patients with high expression of miR-135a experienced
early recurrence (71%), while early recurrence was less fre-
quent in patients with low miR-135a expression (3 out of
9 patients, 33%). Due to the small number of patients,
Cox regression analysis did not reach the defined level of
significance (HR 2.9, 95% CI 0.7–12.4, p = 0.146). How-
ever, the Kaplan-Meier curve showed a robust trend with
a mean time to recurrence of 11.6 ± 4.1 months in patients
with T1 or T2 tumor status and high expression of miR-
135a compared to 24.8 ± 4.4 months in patients with T1
or T2 tumor status and low expression of miR-135a
(see Additional file 1: Figure S1 and Table S1).
Discussion
The risk of recurrence is crucial for the prognosis of
patients undergoing HCC resection and the most
Table 2 Histological characteristics of patients with and without
































aIn three patients complete histological analysis was not possible due to
tumor necrosis after prior TACE. Abbreviations: TACE
transarterial chemoembolization
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important parameter to select patients for adjuvant ther-
apy. Therefore, we investigated putative markers to stratify
the risk of early recurrence and quantified the expression
of selected miRNAs in the resected HCC in comparison
to the surrounding non-cancerous liver tissue.
Patient characteristics
Age, gender, and underlying liver disease are equally con-
tributed within our study and resemble other cohorts of
patients resected for HCC [23]. The fraction of patients
with liver cirrhosis is low (37%) reflecting patient selection
for curative resection. Patients with large tumors and cir-
rhosis are not suitable for resection, while on the other
hand resection is the recommended first-line treatment
for patients with HCC without underlying liver cirrhosis
also for large tumors [24]. In addition, a high number of
patients with liver cirrhosis are not suitable candidates for
resection because of portal hypertension.
T3 and resection status are associated with early
recurrence of HCC
Microvascular invasion and macroscopic multifocal tumor
dissemination, especially satellite nodules near the primary
tumor lesion, have been established to be predictive for
HCC recurrence after resection [25, 26]. Therefore, we in-
vestigated the predictive value of histopathological markers.
As expected, T3 status was significantly associated with
early recurrence. However, in our small cohort of patients,
microvascular invasion did not show a statistically signifi-
cant association with early recurrence. However, microscop-
ically incomplete resection (R1 status) was associated with
early recurrence, underlining again the importance of
complete tumor resection. Over the last years, other histo-
pathological features have been proposed to be predictive
for early recurrence. For example, a higher incidence of
early recurrence or a worse outcome has been reported for
tumors stained positive for cytokeratin 19, a putative stem-
ness maker [27]. Several publications have also revealed and
refined specific gene signatures predicting recurrence of
HCC [4, 28]. Along this line, Villanueva et al. have proposed
a composite model of clinical parameters and gene signa-
tures to assess the risk of early recurrence in HCC [29].
Fig. 2 Expression levels of micro RNAs. Relative expression levels of miR-21, miR-122, miR-125b, and miR-135a in HCC tissue vs. the surrounding
non-cancerous liver tissue (compared to healthy liver control, calibrated as 1). *p < 0.05
Table 3 Cox Regression analysis
Hazard ratio 95% CI p-value
miR-135a high 4.2 1.2–14.8 0.024










Cox regression analysis on the influence of high expression of miR-135a and
miR-21 on the recurrence of HCC, n = 26. Abbreviations: CI confidence interval
Fig. 3 Kaplan-Meier curves. Recurrence free survival (RFS) of patients
with high vs. low expression of miR-135a (a) and miR-21 (b) in HCC
tissue, n = 26. Abbreviations: HR, hazard ratio; CI, confidence interval
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High intratumoral expression of miR-135a predicts early
HCC recurrence
In our study, we investigated the expression of selected
miRNAs in HCC tissue in comparison to the corre-
sponding surrounding non-cancerous liver tissue of the
same patient. We selected liver tissue from three pa-
tients without any sign of fibrosis or significant steatosis
to serve as calibrator for baseline hepatic expression
levels. The expression patterns of miR-21, miR-122, and
miR-125b in HCC tissue and the surrounding non-
cancerous liver tissue were as expected based on prior
publications. A predictive value of these miRNAs regard-
ing early recurrence of HCC was not evident in our
study. In contrast, our data reveal for the first time a
robust association between the risk of early HCC recur-
rence and high intratumoral expression of miR-135a.
Noteworthy, the predictive power was independent of
cirrhosis, presence of microvascular invasion, and resec-
tion status. In addition, our data demonstrate that pa-
tients with T1 and T2 tumors are more likely to develop
recurrence and to have a shorter time to recurrence if
miR-135a expression is increased (the data did not reach
the level of statistical significance). As published
recently, miR-135a is linked to vascular invasion and
metastases in HCC. High miR-135a levels favour inva-
sive and metastatic growth of HCC cells in vitro and are
correlated with malignant portal vein thrombosis, pos-
sibly by directly targeting MTSS1 [20]. Other targets of
miR-135a investigated in vitro are forkhead box O1,
matrix metalloproteinase-2, AKT pathway, and Krüppel-
like factor-4 [21, 22]. Therefore, from a functional per-
spective, elevated levels of miR-135a might induce early
formation of microscopic HCC dissemination via several
pathways, and thus, result in early HCC recurrence
after curative resection. This might be especially im-
portant for patients with small tumors (T1/2) because
miR-135a expression might control the risk for early
intrahepatic spread.
It should be noted, that also other miRNAs have re-
cently been described to be associated with recurrence
of HCC, supporting a crucial role of these small mole-
cules in the biology of HCC. For example, decreased
expression of miR-126 in HCC has been correlated with
HCC recurrence and poor survival after liver transplant-
ation [30]. In another study, a predictive score combin-
ing the expression levels of miR-214, miR-3187 and the
Milan criteria was proposed to stratify patients accord-
ing to their risk for recurrence of HCC and death after
liver transplantation [31].
The role of circulating miRNAs in peripheral blood for
the detection of HCC or other liver diseases has also been
investigated [32]. Especially serum miR-486-5p, in com-
bination with alpha-fetoprotein levels and microvascular
invasion, was found to predict risk of recurrence [33].
Following this approach, a highly sensitive digital droplet
PCR of serum samples from our patients with elevated
intratumoral miR-135a expression remained negative in
our hands (data not shown). In contrast to other circulat-
ing miRNAs, this might be due to the very low expression
of miR-135a in the tumor, resulting in only marginal
quantities secreted into the peripheral blood.
Adjuvant systemic therapy for patients undergoing
resection of HCC
Adjuvant therapy with the tyrosine kinase inhibitor
sorafenib was investigated in the STORM trial (Adjuvant
Sorafenib for Hepatocellular Carcinoma after Resection
or Ablation: A Phase 3, Randomised, Double-blind,
Placebo-controlled Trial; NCT00692770). Unfortunately,
the trial was negative and it is still unclear, which
patients might profit from adjuvant therapy [34]. Note-
worthy, patients in the STORM trial were not selected
based on intratumoral biomarkers. To this regard,
Hoshida et al. identified a specific expression profile in
the surrounding non-cancerous liver tissue of patients
undergoing resection for HCC that predicts late recur-
rence (>2 years). However, the study did not identify a
specific expression signature within the resected HCC to
predict overall recurrence or early recurrence [3, 4].
Limitations and benefits of our study
Our study is monocentric and therefore entails only a
small cohort of patients. On the other hand, we were
able to derive a strong and statistically significant result
for the association between high miR-135a expression
and early recurrence. Our study is based on longitudinal
data and the investigation of paired tissue samples from
each patient (HCC tissue and the surrounding non-
cancerous liver tissue).
Conclusion
After curative intended liver resection for HCC up to
70% of patients suffer from recurrence within 2 years.
Following the current paradigm, synchronous intrahepa-
tic microscopic metastases at the time of resection,
whose growth is driven by liver regeneration, are the
most frequent source for early recurrence and hamper
the outcome of resection. Until now, there is no estab-
lished adjuvant therapy to improve this rather dismal
prognosis. In conclusion, we revealed that high expres-
sion of miRNA-135a in HCC tissue correlates with a
significant 4.2-fold increased risk of early recurrence and
a significant reduction in time to recurrence after
complete resection. Therefore, miRNA-135a might
help to stratify and to identify patients who possibly
benefit from adjuvant therapy after liver resection and
prospective studies are needed to investigate this issue.
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